PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Vitamin D Status, Supplementation and Cardiovascular Disease.

Abstract This review was conducted to assess the dose-response relationship between vitamin D and cardiovascular disease (CVD) outcomes in humans: Prospective cohort studies indicate a multivariable-adjusted non-linear increase in CVD events at levels of circulating 25-hydroxyvitamin D [25(OH)D] of less than 50 nmol/l. However, Mendelian randomization studies do not support these findings. Although meta-analyses of randomized controlled trials (RCTs) do not rule out small beneficial vitamin D effects on surrogate parameters of CVD risk, such as arterial stiffness, at vitamin D doses equivalent to 1,000-5,333 IU daily, other meta-analyses of RCTs show no reduction in CVD events by vitamin D supplementation. Notably, some cohort studies and a recent RCT provide evidence for harmful effects of vitamin D on CVD outcomes at 25(OH)D levels in excess of 100 nmol/l. In conclusion, more studies in individuals with a deficient 25(OH)D level (i.e. <30 nmol/l) are needed, but caution is necessary regarding supplementation with vitamin D doses achieving a 25(OH)D level which exceeds 100 nmol/l.
PMID
Related Publications

Clinical utility of vitamin d testing: an evidence-based analysis.

Prospective study of serum 25-hydroxyvitamin D level, cardiovascular disease mortality, and all-cause mortality in older U.S. adults.

The role of vitamin D for cardiovascular disease and overall mortality.

The Biphasic Effect of Vitamin D on the Musculoskeletal and Cardiovascular System.

Effectiveness and safety of vitamin D in relation to bone health.

Authors

Mayor MeshTerms
Keywords

25-hydroxyvitamin D

Mendelian randomization

Vitamin D

cardiovascular disease

mortality

review

supplementation

Journal Title anticancer research
Publication Year Start




PMID- 29374756
OWN - NLM
STAT- In-Process
LR  - 20180201
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 38
IP  - 2
DP  - 2018 Feb
TI  - Vitamin D Status, Supplementation and Cardiovascular Disease.
PG  - 1179-1186
AB  - This review was conducted to assess the dose-response relationship between
      vitamin D and cardiovascular disease (CVD) outcomes in humans: Prospective cohort
      studies indicate a multivariable-adjusted non-linear increase in CVD events at
      levels of circulating 25-hydroxyvitamin D [25(OH)D] of less than 50 nmol/l.
      However, Mendelian randomization studies do not support these findings. Although 
      meta-analyses of randomized controlled trials (RCTs) do not rule out small
      beneficial vitamin D effects on surrogate parameters of CVD risk, such as
      arterial stiffness, at vitamin D doses equivalent to 1,000-5,333 IU daily, other 
      meta-analyses of RCTs show no reduction in CVD events by vitamin D
      supplementation. Notably, some cohort studies and a recent RCT provide evidence
      for harmful effects of vitamin D on CVD outcomes at 25(OH)D levels in excess of
      100 nmol/l. In conclusion, more studies in individuals with a deficient 25(OH)D
      level (i.e. &lt;30 nmol/l) are needed, but caution is necessary regarding
      supplementation with vitamin D doses achieving a 25(OH)D level which exceeds 100 
      nmol/l.
CI  - Copyright(c) 2018, International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Zittermann, Armin
AU  - Zittermann A
AD  - Clinic for Thoracic and Cardiovascular Surgery, Heart and Diabetes Center North
      Rhine-Westphalia, Ruhr-University of Bochum, Bad Oeynhausen, Germany
      [email protected]
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
OTO - NOTNLM
OT  - *25-hydroxyvitamin D
OT  - *Mendelian randomization
OT  - *Vitamin D
OT  - *cardiovascular disease
OT  - *mortality
OT  - *review
OT  - *supplementation
EDAT- 2018/01/29 06:00
MHDA- 2018/01/29 06:00
CRDT- 2018/01/29 06:00
PHST- 2017/11/06 00:00 [received]
PHST- 2017/11/29 00:00 [revised]
PHST- 2017/11/30 00:00 [accepted]
PHST- 2018/01/29 06:00 [entrez]
PHST- 2018/01/29 06:00 [pubmed]
PHST- 2018/01/29 06:00 [medline]
AID - 38/2/1179 [pii]
AID - 10.21873/anticanres.12338 [doi]
PST - ppublish
SO  - Anticancer Res. 2018 Feb;38(2):1179-1186. doi: 10.21873/anticanres.12338.